



www.asianpubs.org

ARTICLE

Efficient Synthesis of 5-(4-(Substituted [1,1'-Biphenyl]-4-yl-methoxy)benzyl)thiazolidine-2,4-diones under Microwave Irradiation using Suzuki Coupling Reaction and their Biological Screening

Mitesh Vekariya[✉], Tejal Bhatt[✉] and Hitendra Joshi[✉]

Asian Journal of Organic & Medicinal Chemistry

Volume: 7

Year: 2022

Issue: 2

Month: April–June

pp: 198–204

DOI: <https://doi.org/10.14233/ajomc.2022.AJOMC-P388>

Received: 25 April 2022

Accepted: 15 June 2022

Published: 29 June 2022

ABSTRACT

In present study, an efficient and greener protocol is developed for the synthesis of 5-(4-(substituted [1,1'-biphenyl]-4-yl-methoxy)benzyl)thiazolidine-2,4-diones by using microwave irradiations. Here, a one-pot reaction between 5-(4-((4-bromobenzyl)oxy)benzyl)thiazolidine-2,4-dione, substituted aryl boronic acid and K_2CO_3 in the presence of toluene:water:ethanol solvents under conventional heating methods and microwave irradiation methods is reported. All the final compounds were characterized by FT-IR, 1H NMR, ^{13}C NMR and mass spectroscopic analysis. The antimicrobial evaluation studies show moderate activities against used microbes.

KEYWORDS

Suzuki coupling reaction, Microwave synthesis, Antimicrobial activity, Thiazolidine-2,4-diones derivatives.

INTRODUCTION

Heterocyclic functioning organic compounds in which oxygen, nitrogen and sulphur atoms containing compounds are broadly assigned in nature and important in the field of biologically active molecules [1]. Among the thiazolidine-2,4-dione (TZD) [2] is the most important heterocyclic moiety with much attention particularly in the treatment of type 2 diabetes [3]. Thiazolidine-2,4-dione derivatives possess a significance role in broad range of pharmacological activity [4]. Therefore, the recent growth of research and enhance the interest for chemist who have prepared a variety of thiazolidinedione's derivatives and evaluated them for their various biological activities. Presently multiple antimicrobial [5] drugs are available in the market, but there is a requirements of the discovery of new lead structures and novel chemical entities which will act as antibacterial agents with better pharmacodynamics [6] and pharmacokinetic [7] properties with minimum side effects.

They shows a number of pharmacological activities such as antimicrobial [8], antitubercular, antioxidant [9], anti-tumor, anticancer [10], antiviral [11], anti-HIV, hyperglycemic [12], anti-inflammatory [13] and antidiabetic [9].

Author affiliations:

Department of Chemistry, Saurashtra University, Rajkot-360005, India

[✉]To whom correspondence to be addressed:

E-mail: tejalbhatt17@gmail.com

Available online at: <http://ajomc.asianpubs.org>

Microwave-irradiation (MW) [14] technique is used to promote the organic chemical reactions and a multiple number of reviews have advocated in organic one-pot synthesis. Organic molecules synthesis using microwave irradiation method has merits over conventional heating method. Microwaves-assisted method provide a powerful way to carry out synthetic chemistry and they gave ability of shorten reaction times, increase reaction yields [15] and facilitate to reactions. Overall, microwave-assisted method allows conducting economical and cleaner reactions.

Efficient C-C bond formation [16] reactions have been in the limelight of catalysis research for the past few decades. Suzuki coupling [17] is one such reaction, in which coupling between an organo-boron reagent and an organic halide or pseudo halide takes place in presence of palladium catalyst, phosphine ligand and a base. Suzuki coupling is one of the most efficient methods for the synthesis of diaryl acetylenes that constitutes important building blocks. Miyaura cross-coupling [18] reaction is one such prominent reaction plays a key role in organic chemistry as well as evolved an important chemistry tool for innumerable applications such as agrochemicals, polymers, synthetic intermediates, etc. are using microwaves and ultrasonic [19].

Pharmacological importance of thiazolidine-2,4-dione derivatives inspired us to synthesize new compounds (V-XVI) under conventional heating and microwave irradiation methods. Herein, a new, rapid and efficient synthetic method for 5-(4-(substituted [1,1'-biphenyl]-4-yl-methoxy)benzyl)thiazolidine-2,4-diones from 5-(4-((4-bromobenzyl)oxy)benzyl)thiazolidine-2,4-dione presence of K_2CO_3 base and $Pd(PPh_3)_4$ catalyst.

EXPERIMENTAL

All chemicals were purchased and used without any further purification. Reactions were monitored by thin layer chromatography (TLC) on silica gel-G plates (G60 F₂₅₄ (Merck)) of 0.5 mm thickness, visualizing was made with ultraviolet light (254 and 365 nm), or with iodine vapour chamber and aq. $KMnO_4$ reagent. Melting point was determined using a Buchi B-540 open capillary apparatus. IR spectra were recorded on a FTIR-8400 S, CE Shimadzu instrument using KBr pellets method and are expressed in cm^{-1} . Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and ^{13}C NMR spectra were recorded on a Bruker Avance 400 MHz and Bruker DRX 101 MHz spectrometer, respectively in deuterated solvents like $CDCl_3$ or $DMSO-d_6$ solvent. For Suzuki coupling the Monowe 300 (Anton Paar) microwave synthesizer was used. Solvents were evaporated with a Buchi rotary evaporator. The purification of all synthesized compounds was performed by borosil glass column having a length about 1000 mm.

Biological assay

Antibacterial assay: The broth dilution method was applied for the evaluation of the antibacterial activity. It is one of the non-automated *in vitro* bacterial susceptibility tests. This technique shows the quantitative result for the amount of antimicrobial agents needed to inhibit specific microorganisms' growth. The screened for their antibacterial activity in triplicate

sets against these bacteria at different concentrations of 1000, 500, 250 and 200 $\mu g/mL$. The drugs which were found to be active in primary analysis were further diluted and evaluated. 10 $\mu g/mL$ suspension was also inoculated on appropriate media and the growth was noted after one or two days. Minimum inhibitory concentration is the lowest concentration, which showed no microbes growth after spot subculture for each drug. The test mixture should contain 100 $\mu g/mL$.

Here, in represent case for evaluating antibacterial activity, the bacterial strains *viz.* *Staphylococcus aureus* MTCC 96 and *Bacillus subtilis* MTCC 441 (Gram-positive); *Escherichia coli* MTCC 443 and *Salmonella typhimurium* MTCC 98 (Gram-negative) were selected. The strains were procured from the department of microbiology, R K University, Rajkot, India.

Antifungal assay: The newly prepared compounds were screened for their antifungal activity as primary screens in six sets against *C. albicans*, *A. niger* and *A. clavatus* at various concentrations of 1000, 500 and 250 $\mu g/mL$. The primary active compounds were similarly diluted to obtain 200 and 100 $\mu g/mL$ concentrations for secondary screening to test in the second set of dilutions against all fungi. Each compound's fungal activity was compared with nystatin as a standard drug, which showed 100, 100 and 100 $\mu g/mL$ MIC against *C. albicans*, *A. niger* and *A. clavatus*, respectively.

In present case evaluation of antifungal activity, *Aspergillus niger* MTCC 282 and *Aspergillus clavatus* MTCC 1323 as fungal strains were selected. The strains were procured from the department of microbiology, R K University, Rajkot, India.

Synthesis of thiazolidine-2,4-dione (I): In 100 mL dry round bottom flask containing 2-chloroacetic acid (5 g, 53 mmol) and thiourea (4 g, 53 mmol), added 30 mL deionized water to dissolve them. Stirred the resulting solution for 10 min at room temperature till it becomes cleared and then added conc. HCl (5 mL) in to the solution in dropwise. Place the round bottom flask on oil bath to refluxed temperature for 10 h. Monitor the reaction by TLC using hexane:ethyl acetate (7:3 mL) as solvent system. After the completion cooled the reaction mixture on ice-bath, filtered the shiny crystal that formed subsequently on cooling and washed with cooled water to afford white shiny crystal as thiazolidine-2-4-dione (I) (m.f.: $C_3H_3NO_2S$; m.p.: 123-125 °C; 5.5 g, 90% yield, white crystal).

Synthesis of (E)-5-(4-hydroxybenzylidene)thiazolidine-2,4-dione (II): In a 250 mL three necked flask equipped with Dean-stark apparatus, added thiazolidine-2-4-dione (I) (5 g, 43 mmol), 4-hydroxy benzaldehyde (5.26 g, 43 mmol) and dry toluene (20 mL), stirred the resultant mixture to form a clear solution. Then added dry piperidine in catalytic amount (0.5 mL) and refluxed the reaction mixture at 110 °C, separate the water, which generates during reaction. After completion of reaction (checked by TLC using hexane:ethyl acetate (7:3 mL) solvent system) cooled it, separated yellow solid and filtered, washed with cooled toluene and dry ethanol to afford pure product as (E)-5-(4-hydroxybenzylidene)thiazolidine-2,4-dione (II) (m.f.: $C_{10}H_7NO_3S$; m.p.: 303-304 °C; 7 g, 73% yield, Yellow solid).

Synthesis of 5-(4-hydroxybenzyl)thiazolidine-2,4-dione (III): (E)-5-(4-hydroxybenzylidene)thiazolidine-2,4-dione (II)

(3 g, 13 mmol) in 50 mL dry stainless steel laboratory autoclave (catalytic hydrogenation apparatus), added 20 mL of HPLC grade methanol and to dissolve the solid. Then added 10% Pd/C (wet) (3 g) to the solution and purged the hydrogen gas up to 250 psi, tight autoclave and put on hot plate with magnetic stirrer at 70 °C for 5 h. After completion of reaction indicate by TLC using hexane:ethyl acetate (8:2 mL solvent system), released excess hydrogen gas in open air and transfer the solution in to glass beaker, followed by filter on high flow clay pad to remove Pd/C catalyst. The filtrate was concentrate under reduced pressure to formed greenish coloured semi-solid, added diethyl ether and triturate, filtered the solid and washed with cooled ether, dried it to get pure **III** (m.f.: C₁₀H₉NO₃S; 80% yield, Greenish solid).

Synthesis of 5-(4-((4-bromobenzyl)oxy)benzyl)thiazolidine-2,4-dione (IV): Dissolved 5-(4-hydroxybenzyl)thiazolidine-2,4-dione (**III**) (2 g, 9 mmol) in 100 mL dry round bottom flask containing dry DMF (20 mL). Then cooled to 0-5 °C using ice-bath, add 4-bromo benzyl bromide (2.7 g, 10.8 mmol) and sodium bicarbonate (2.3 g, 27 mmol). Stirred the solution at room temperature for 12 h. The reaction was monitored by using TLC with hexane:ethyl acetate (7:3) solvent system. After completion poured the reaction mixture into a crushed ice with stirring, added ethyl acetate to extract the product, separate the organic layer and washed with brine solution twice and dried it on anhydrous sodium sulphate. Concentrated the solution under reduced pressure to get residue, added hexane with trituration to remove excess of 4-bromo benzyl bromide, filtered the solid, washed with hexane and dried it to get **IV** (m.f.: C₁₇H₁₄BrNO₃S; 90% yield, white solid) (**Scheme-I**).

General procedure (Suzuki coupling) for synthesis of 5-(4-(Substituted-[1,1'-biphenyl]-4-ylmethoxy)benzyl)thiazolidine-2,4-diones (V-XVI)


Microwave irradiation (MW) method: Prepare a solvent mixture of toluene (5 mL), ethanol (0.5 mL) and distilled water (0.5 mL) in standard 10 mL dry borosilicate glass microwave vial sealed with PTFE-coated silicon septum, stirred to mix it. Then added 5-(4-((4-bromobenzyl)oxy)benzyl)thiazolidine-2,4-dione (**IV**) (500 mg, 1.3 mmol), substituted aryl boronic acid (1.95 mmol), K₂CO₃ (450 mg, 3.25 mmol) and degassed the solution by purging of N₂ gas for 15 min, the solution turns to light yellow coloured followed by the addition of [Pd[P(Ph₃)₄] (150 mg, 0.1%) as catalyst and sealed the vial, solution turns to light brown coloured. Put the vial in silicon carbide vessels in microwave at 110 °C for 6 min. After

completion (checked by TLC using ethyl acetate:hexane (3:7 mL) solvent system), poured the reaction mixture into crushed ice and extracted the product in ethyl acetate (3 × 15 mL). Separated the organic layer and washed with brine and dried it on anhydrous sodium sulphate, concentrated in vacuum to get brown coloured residue. Purified the final product was using column chromatography 10% ethyl acetate:hexane eluent system to get pure thiazolidinediones derivatives (**V-XVI**).


Conventional heating (CH) method: Prepared a solvent mixture of toluene (5 mL), ethanol (0.5 mL) and distilled water (0.5 mL) in vial, stirred to mix it. Then added 5-(4-((4-bromobenzyl)oxy)benzyl)thiazolidine-2,4-dione (**IV**) (500 mg, 1.3 mmol), substituted aryl boronic acid (1.95 mmol), K₂CO₃ (450 mg, 3.25 mmol) and degassed the solution by purging of N₂ gas for 15 min, the solution turns to light yellow coloured. Followed by the addition of [Pd[P(Ph₃)₄] (150 mg, 0.1%) as catalyst and sealed the vial, solution turns to light brown coloured. The mixture was stirred and heated to 110 °C for 60 min. After completion (checked by TLC using ethyl acetate:hexane (3:7 mL) solvent system), poured the reaction mixture into crushed ice and extract the product in ethyl acetate (3 × 15 mL). Separated the organic layer and washed with brine and dried it on anhydrous sodium sulphate, concentrated in vacuum to get brown coloured residue. Purified the final product was using column chromatography 10% ethyl acetate:hexane eluent system to get pure thiazolidinediones derivatives (**V-XVI**) (**Scheme-II**).

5-(4-((4'-Methoxy-[1,1'-biphenyl]-4-yl)methoxy)benzyl)thiazolidine-2,4-dione (V): White solid; yield: MW = 90%, CH = 69%; m.p.: 106-108 °C; ¹H NMR (400 MHz, DMSO-*d*₆): 3.09-3.21 (m, 2H, -CH₂ (A)), 3.79 (s, 3H (B), -OCH₃), 4.58-4.71 (dd, 2H, -CH₂ (C), *J* = 14.8, 36.4 Hz), 4.99 (s, 1H, -CH (D)), 6.67-6.69 (d, 2H (E), Ar-H, *J* = 10.4 Hz), 7.01-7.09 (m, 6H (F), Ar-H), 7.51-7.59 (m, 4H (G), Ar-H), 9.42 (s, 1H (H), -NH-); ¹³C NMR (101 MHz, DMSO-*d*₆): δ 35.8 (C1), 43.98 (C2), 51.25 (C3), 55.12 (C4), 114.3 (C5), 115.16 (C6), 125.93 (C7), 126.22 (C8), 127.71 (C9), 130.6 (C10), 132.03 (C11), 133.68 (C12), 139.10 (C13), 156.52 (C14), 158.91 (C15), 171.10 (C16), 173.79 (C17); IR (KBr, *v*_{max}, cm⁻¹): 3414 (N-H *str.*, *sec.* cyclic imide (m)), 3010, 2914 (C-H, *str.*, aromatic), 2843 (C-H, *str.*, alkane), 1757, 1678 (C=O, *str.*, 5-membered cyclic imide), 1608, 1500, 1448 (C=C, *str.*, aromatic), 1384 (C-H, bend.), 1153 (C-S, *str.*), 976 (*p*-subs. benzene ring); Mass (*m/z*): Exact mass: 419, Found mass: 419.

4'-((4-((2,4-Dioxothiazolidin-5-yl)methyl)phenoxy)methyl)-[1,1'-biphenyl]-4-carbonitrile (VI): White solid;



Scheme-I: Suzuki-Miyaura coupling of **IV** with phenyl boronic acid



Scheme-II

Yield: MW = 78%, CH = 65%; m.p.: 108-110 °C; $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 3.14-3.30 (m, 2H, $-\text{CH}_2$ (A)), 4.61-4.74 (q, 2H, $-\text{CH}_2$ (B)), 4.99-5.02 (q, 1H, $-\text{CH}$ (C)), 6.66-6.68 (d, 2H (D), Ar-H, $J_{DE} = 8$ Hz), 7.01-7.03 (d, 2H (E), Ar-H, $J_{ED} = 8$ Hz), 7.12-7.14 (d, 2H (F), Ar-H, $J_{FG} = 8$ Hz), 7.65-7.67 (d, 2H (G), $J_{GF} = 8$ Hz), 7.85-7.87 (d, 2H (H), $J_{HI} = 8$ Hz), 7.93-7.95 (d, 2H (I), $J_{IH} = 8$ Hz), 9.41 (s, 1H (J), $-\text{NH}-$); $^{13}\text{C NMR}$ (101 MHz, $\text{DMSO-}d_6$): δ 35.2, 56.76, 70.08, 110.5, 115.2, 117.6, 125.22, 130.5, 131.06, 135.12, 143.02, 155.15, 172.04, 174.67; IR (KBr, ν_{max} , cm^{-1}): 3377 (N-H *str.*, *sec.* cyclic imide (m)), 3016 (C-H, *str.*, aromatic), 2922 (C-H, *str.*, alkane), 2231 ($-\text{CN}$ *str.*), 1743, 1674 (C=O, *str.*, 5-member cyclic imide), 1606, 1514, 1446 (C=C, *str.*, aromatic), 1354 (C-H, bend.), 1220 (C-O *str.*), 1153 (C-S, *str.*), 976 (*p*-subs. benzene ring); Mass (m/z): Exact mass: 414, Found mass: 414.

5-(4-([1,1'-Biphenyl]-4-ylmethoxy)benzyl)thiazolidine-2,4-dione (VII): White solid; Yield: MW = 82%, CH = 70%; m.p.: 154-156 °C; $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 3.10-3.31 (m, 2H, $-\text{CH}_2$ (A)), 4.60-4.73 (q, 2H, $-\text{CH}_2$ (B)), 5.0 (d, 1H, $-\text{CH}$ (C), $J_{CA} = 2.8$ Hz), 6.67-6.69 (d, 2H (D), Ar-H, $J_{DE} = 8$ Hz), 6.93-7.03 (dd, 4H (E), Ar-H, $J_{ED} = 7.6, 30.8$ Hz), 7.37 (d, 1H (F), Ar-H, $J_{FH} = 7.2$ Hz), 7.45-7.48 (t, 2H (G), Ar-H, $J_{GE} = 7.6$ Hz), 7.56-7.58 (d, 2H (H), Ar-H, $J_{HI} = 8$ Hz), 7.63-7.65 (d, 2H (I), Ar-H, $J_{IH} = 8$ Hz), 9.42 (s, 1H, $-\text{NH}-$); $^{13}\text{C NMR}$ (101 MHz, $\text{DMSO-}d_6$): δ 35.84 (C1), 43.96 (C2), 51.25 (C3), 115.16 (C4), 125.91 (C5), 126.76 (C6), 127.47 (C7), 127.77 (C8), 128.91 (C9), 130.62 (C10), 134.46 (C11), 139.71 (C12), 139.71 (C13), 156.52 (C14), 171.12 (C15), 173.80 (C16); IR (KBr, ν_{max} , cm^{-1}): 3383 (N-H *str.*, *sec.* cyclic imide (m)), 3030 (C-H, *str.*, aromatic), 2922 (C-H, *str.*, alkane), 1739, 1668 (C=O, *str.*, 5-member cyclic imide), 1612, 1591, 1514, 1433 (C=C, *str.*, aromatic), 1394 (C-H, bend.), 1269 (C-O, *str.*), 1149 (C-S, *str.*), 969 (*p*-subs. benzene ring); Mass (m/z): Exact mass: 389.47, Found mass: 389.

5-(4-((4'-Fluoro-[1,1'-biphenyl]-4-yl)methoxy)benzyl)thiazolidine-2,4-dione (VIII): White solid; Yield: MW = 84%,

CH = 72%, m.p.: 111-113 °C; $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 3.01-3.07 (dd, 1H, $-\text{CH}_2$, $J = 8.4, 14$ Hz), 3.26-3.31 (dd, 1H, $-\text{CH}_2$, $J = 3.6, 14$ Hz), 4.36-4.39 (dd, 1H, $-\text{CH}$, $J = 3.6, 8.4$ Hz), 4.60-4.68 (q, 2H, $-\text{CH}_2$), 4.88 (s, 1H, $-\text{NH}-\text{C}=\text{O}$), 6.58-6.60 (d, 2H, Ar-H, $J = 8$ Hz), 6.94-6.96 (d, 2H, $J = 8$ Hz), 7.03-7.07 (t, 2H, $J = 8.4$ Hz), 7.18-7.22 (t, 2H, Ar-H, $J = 8$ Hz), 7.37-7.47 (m, 4H, Ar-H); $^{13}\text{C NMR}$ (101 MHz, $\text{DMSO-}d_6$): 37.44, 44.83, 51.59, 115.53, 115.84, 127.23, 128.68, 130.76, 133.96, 136.68, 140.02, 155.02, 161.34, 163.79, 171.06, 173.74; IR (KBr, ν_{max} , cm^{-1}): 3408 (N-H *str.*, *sec.* cyclic imide (m)), 3319 (C-H, *str.*, aromatic), 1751, 1654 (C=O, *str.*, 5-membered cyclic imide), 1492 (C-H, bend.), 1259 (C-O, *str.*), 1093 (C-S, *str.*), 804 (*p*-subs. benzene ring); Mass (m/z): Exact mass: 407, Found mass: 407.

5-(4-((3',4',5'-Trifluoro-[1,1'-biphenyl]-4-yl)methoxy)benzyl)thiazolidine-2,4-dione (X): Yellow solid; Yield: MW = 78%, CH = 65%, m.p.: 127-129 °C; $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 3.13-3.85 (q, 2H, $-\text{CH}_2$), 4.61-4.73 (dd, 2H, $-\text{CH}_2$, $J = 15.2, 32.4$ Hz), 5.01 (s, 1H, $-\text{CH}$), 6.68 (s, 2H, Ar-H), 7.01-7.12 (t, 4H, Ar-H), 7.64 (s, 4H, Ar-H), 9.43 (s, 1H, $-\text{NH}-\text{C}=\text{O}$); $^{13}\text{C NMR}$ (101 MHz, $\text{DMSO-}d_6$): δ 28.96, 35.82, 43.83, 51.24, 111.19, 115.15, 125.84, 126.87, 127.82, 128.25, 130.61, 136.08, 137, 139, 149, 151.75, 156.50, 171.11, 173.75; IR (KBr, ν_{max} , cm^{-1}): 3485 (N-H *str.*, secondary cyclic imide (m)), 3441 (C-H, *str.*, aromatic), 3055, 2960 (C-H, *str.*, alkane), 1747, 1651 (C=O, *str.*, 5-member cyclic imide), 1533 (C=C, *str.*, aromatic), 1332 (C-H, bend.), 1259 (C-O, *str.*), 1037 (C-S, *str.*), 800 (*p*-subs. benzene ring); Mass (m/z): Exact mass: 443, Found mass: 443.

5-(4-((3'-Amino-[1,1'-biphenyl]-4-yl)methoxy)benzyl)thiazolidine-2,4-dione (XI): Grey solid; Yield: MW = 76%, CH = 62%, m.p.: 129-131 °C; $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 3.06-3.14 (q, 1H, $-\text{CH}_2$ (A)), 3.27-3.39 (dd, 1H, $-\text{CH}_2$ (A), $J_{AC} = 4, 14$ Hz), 4.58-4.71 (q, 2H (B), $-\text{CH}_2$), 4.96-5.01 (dd, 1H, $-\text{CH}$ (C), $J_{CA} = 4.4, 16$ Hz), 5.17 (s, 2H (D), $-\text{NH}_2$), 6.55-6.58 (dd, 1H (E), Ar-H, $J_{EH} = 1.2, J_{EI} = 8$ Hz), 6.67-6.69 (d, 2H (F), Ar-H, $J_{FI} = 8$ Hz), 6.74-6.76 (d, 1H (G), Ar-H, $J_{GH} = 8$ Hz), 6.80-6.81 (t, 1H (H), Ar-H, $J_{HI} = 2$ Hz), 7.01-7.03 (d, 2H (I),

$J_{IF} = 8$ Hz), 7.08-7.12 (m, Ar-H, 3H (J)), 7.48-7.51 (d, 2H (K), $J_{KJ} = 12$ Hz), 9.41 (s, 1H (L), -NH-); ^{13}C NMR (101 MHz, DMSO- d_6): δ 35.89 (C1), 44.00 (C2), 51.27 (C3), 112 (C4), 113.19 (C5), 114.33 (C6), 115.04 (C7), 125.99 (C8), 126.52 (C9), 129.38 (C10), 130.01 (C11), 132.03 (C12), 134.07 (C13), 140.38 (C14), 140.44 (C15), 149.06 (C16), 156.50 (C17), 171.12 (C18), 173.82 (C19); IR (KBr, ν_{max} , cm^{-1}): 3338 (N-H, *str.* amine), 3305 (N-H *str.*, *sec.* cyclic imide (m)), 1747, 1681 (C=O, *str.*, 5-membered cyclic imide), 1516 (C=C, *str.*, aromatic), 771 (*m*-subs. benzene ring); Mass (m/z): Exact mass: 404, Found mass: 404.

5-(4-((3'-Fluoro-[1,1'-biphenyl]-4-yl)methoxy)benzyl)thiazolidine-2,4-dione (XIII): White solid; Yield: MW = 80%, CH = 69%, m.p.: 110-112 °C; ^1H NMR (400 MHz, DMSO- d_6): δ 3.10-3.31 (qq, 2H, -CH₂), 4.61-4.74 (q, 2H, -CH₂), 4.99-5.02 (q, 1H, -CH), 6.67-6.69 (d, 2H, Ar-H, $J = 8$ Hz), 7.01-7.11 (dd, 4H, Ar-H, $J = 8$ Hz), 7.20-7.21 (t, 1H, Ar-H), 7.49-7.51 (d, 3H, $J = 8$ Hz), 7.61-7.63 (d, 2H, Ar-H, $J = 8$ Hz), 9.43 (s, 1H, -NH-); ^{13}C NMR (101 MHz, DMSO- d_6): δ 35.82, 43.91, 51.25, 113.43, 114.28, 115.16, 122.71, 125.86, 126.88, 127.80, 130.79, 135.13, 137.98, 142.19, 156.52, 161.45, 163.87, 171.12, 173.77; IR (KBr, ν_{max} , cm^{-1}): 3441 (N-H *str.*, *sec.* cyclic imide (m)), 3352 (C-H, *str.*, aromatic), 2964 (C-H, *str.*, alkane), 1749, 1662 (C=O, *str.*, 5-membered cyclic imide), 1591, 1502 (C=C, *str.*, aromatic), 1334, 1261 (C-H bend., 1222 (C-O, *str.*), 1101 (C-S, *str.*), 804 (*p*-subs. benzene ring); Mass (m/z): Exact mass: 407, Found mass: 407.

5-(4-((2',4'-Dichloro-[1,1'-biphenyl]-4-yl)methoxy)benzyl)thiazolidine-2,4-dione (XV): Light green solid; Yield: MW = 79%, CH = 66%, m.p.: 97-99 °C; ^1H NMR (400 MHz, DMSO- d_6): δ 3.15-3.38 (t, 2H, -CH₂, $J = 30$ Hz), 4.67-4.71 (d, 2H, -CH₂, $J = 16$ Hz), 5.02 (s, 1H, -CH), 6.08 (s, 2H, Ar-H), 7.03-7.50 (m, 8H, Ar-H), 7.73 (s, 1H, Ar-H), 9.39 (s, 1H, -NH-C=O); ^{13}C NMR (101 MHz, DMSO- d_6): 35.84, 43.95, 51.31, 115.16, 125.90, 127.03, 127.62, 129.27, 130.60, 132.32, 132.94, 135.13, 136.76, 138.28, 156.50, 171.14, 173.82; IR (KBr, ν_{max} , cm^{-1}): 3369 (N-H *str.*, *sec.* cyclic imide (m)), 3304 (C-H, *str.*, aromatic), 2845 (C-H, *str.*, alkane), 1747, 1678 (C=O, *str.*, 5-membered cyclic imide), 1612-1514 (C=C, *str.*, aromatic), 1381-1334 (C-H bend., 1219 (C-O, *str.*), 1141 (C-S, *str.*), 968, 806, 769 (1,2,4-trisubs. benzene ring); Mass (m/z): Exact mass: 458, Found mass: 458.

5-(4-((4'-Ethyl-[1,1'-biphenyl]-4-yl)methoxy)benzyl)thiazolidine-2,4-dione (XVI): Light yellow solid; Yield: MW = 90%, CH = 75%, m.p.: 109-111 °C; ^1H NMR (400 MHz, DMSO- d_6): δ 1.29-1.33 (t, 3H, -CH₃, $J = 8$ Hz), 2.70-2.75 (q, 2H, -CH₂), 3.11-3.16 (q, 1H, -CH₂), 3.35-3.39 (dd, 1H, -CH₂, $J = 3.2, 14$ Hz), 4.44-4.47 (q, 1H, -CH), 4.71-4.80 (q, 2H, -CH₂), 5.91 (s, 1H, -NH-), 6.69-6.71 (d, 2H, Ar-H, $J = 12$ Hz), 7.02-7.04 (d, 2H, Ar-H, $J = 12$ Hz), 7.30-7.32 (d, 4H, Ar-H, $J = 8$ Hz), 7.54-7.56 (d, 4H, Ar-H, $J = 7.6$ Hz); ^{13}C NMR (101 MHz, DMSO- d_6): 15.16, 28.54, 37.39, 44.95, 51.68, 115.61, 127.22, 128.74, 130.75, 133.58, 137.89, 140.93, 143.71, 155.31, 171.50, 174.02; IR (KBr, ν_{max} , cm^{-1}): 3338 (N-H *str.*, *sec.* cyclic imide (m)), 1747, 1678 (C=O, *str.*, 5-membered cyclic imide), 1514 (C=C, *str.*, aromatic), 1386, 1382 (C-H bend., 1219 (C-O, *str.*), 1151 (C-S, *str.*), 970 (*p*-subs. benzene ring); Mass (m/z): Exact mass: 417, Found mass: 417.

RESULTS AND DISCUSSION

In present work, some new 5-substituted thiazolidinedione's derivatives were synthesized. The main nucleus of compounds is a thiazolidinedione's, which is formed by cyclization between thiourea and chloroacetic acid. Thiazolidine-2,4-diones possess an active methylene group, so both hydrogen atom easily replace with oxygen of benzaldehyde to get exocyclic double bond on ring. Which on further alkylation on hydroxyl group to get the product as a scaffold. The free bromine undergoes Suzuki-miyaura coupling with phenyl boronic acid to afforded series of new 5-substituted thiazolidinedione's derivatives (V-XVI).

The first step of **Scheme-I** is the synthesis of thiazolidine-2,4-dione (**I**), which is heterocyclic nucleus in target molecule. In thiazolidinedione's the 5th membered in ring is methylene group *i.e.* -CH₂, which behaves as an active methylene because of presence of neighbouring carbonyl and highly electronegative sulphur atom. Both hydrogens are easily replaced by aryl aldehyde (aldol type reaction) in base catalyst. Compound **II** was synthesized by this phenomenon. In third step, the exocyclic double bond on thiazolidinedione's was reduced by the catalytic hydrogenation by using autoclave to afford 5-(4-hydroxybenzyl)thiazolidine-2,4-dione (**III**). Followed by the alkylation of hydroxyl group by 4-bromobenzyl bromide under basic condition to give 5-(4-((4-bromobenzyl)oxy)benzyl)thiazolidine-2,4-dione (**IV**), which is a scaffold for both series. In final step of scheme one is an microwave assisted suzuki-miyaura coupling of compound **IV** with substituted aryl boronic acid using Pd complex catalyst to got final molecules as 5-(4-(substituted [1,1'-biphenyl]-4-ylmethoxy)benzyl)thiazolidine-2,4-diones (V-XVI).

Reaction optimization: Table-1 shows the number of experiments which were performed for optimizing the reaction condition by changing solvents ratio, bases, catalyst, temperature with time. Different reaction conditions were optimized like room temperature, ultrasonic reflux and microwave conditions. It was observed that microwave conditions are better compared to other conditions. The solvents used were toluene, water, ethanol, isopropyl alcohol, DMM and dioxane with binary mixture of two or more solvents by keeping water constant. The base catalysts were K₂CO₃, Na₂CO₃ and Cs₂CO₃ used, in some experiments TBAB was also added as phase transfer catalyst. Amongst all experiments, entry-8 (Table-1) gives maximum yield by using solvent mixture toluene:water:ethanol (5:0.5:0.5 mL), K₂CO₃ as base and Pd(PPh₃)₄ as catalyst at 110 °C for 6 min in microwave irradiated to afford 90% of yield.

All the synthesized compounds were characterized by various spectrometric techniques like ^1H NMR, ^{13}C NMR, IR, as well as mass spectroscopy. The data obtained are very well supported to final molecules. In ^1H NMR shows very sharp peak at most probable chemical shift value (δ ppm). Due to chirality in molecule the methylene proton non-equivalency are proved by ^1H NMR. Some characteristic peaks in ^1H NMR between 9 to 10 δ ppm shows an -NH- (cyclic amidic proton), also in some spectra the disappearance of -NH- proton by deuterium labeling is one of the major evidence towards the

TABLE-1
OPTIMIZATION TABLE FOR COMPOUND V^a

Entry	Solvent	Base	Catalyst	Condition	Temp. (°C)	Time (min)	Yield ^b (%)
1	Toluene:water (9:1 mL)	Na ₂ CO ₃	Pd(PPh ₃) ₄	RT	110	80	52
2	Toluene:water:ethanol (9:0.5:0.5 mL)	K ₂ CO ₃	Pd(PPh ₃) ₄	Reflux	110	60	68
3	THF:water (9:1 mL)	Na ₂ CO ₃	PdCl ₂ (PPh ₃) ₂	Ultrasonic	65	45	72
4	Toluene:water (9.5:0.5 mL)	Na ₂ CO ₃ + TBAB	Pd(PPh ₃) ₄	Microwave ^a	105	10	80
5	IPA:water (9:1 mL)	K ₂ CO ₃	Pd(OAc) ₂ + PPh ₃	RT	80	80	64
6	DMM:water (9:1 mL)	Na ₂ CO ₃	PdCl ₂ (PPh ₃) ₂	Reflux	60	60	80
7	Dioxane:water (9:1 mL)	Cs ₂ CO ₃	Pd ₂ (dba) ₃	Ultrasonic	100	45	82
8	Toluene:water:ethanol (9:0.5:0.5 mL)	K ₂ CO ₃	Pd(PPh ₃) ₄	Microwave ^a	110	6	90
9	DMM:water (9:1 mL)	Cs ₂ CO ₃ + TBAB	PdCl ₂ (PPh ₃) ₂ + PPh ₃	Microwave ^a	60	8	78
10	Toluene:water (9:1 mL)	Na ₂ CO ₃	Pd(PPh ₃) ₄	Microwave ^a	110	8	65

^aExperiments were performed under Microwave condition, ^bIsolated yield

synthesized molecules. In ¹³C NMR spectra, two peaks at the highest δ ppm at about 170 for two carbonyl groups. The IR spectra the functional group pattern around 3300 cm⁻¹ for -NH-starching frequency, also near 1700 cm⁻¹ for carbonyl group. In some compounds, the possible mass fragments also evidence toward formation of targeted compounds (Table-2).

Biological evaluation

Antibacterial activity: The MIC values of all the synthesized compounds (V-XVI) and standard drugs against selected

microbes are presented in Table-3. The result revealed that some synthesized compounds were much potent towards the bacterial strains as compared to the standard drugs. The compounds VI, XII (100 µg/mL) and VII, XVI (100 µg/mL) were found to be more active against *B. subtilis* with respect to the standard drug ampicillin. Compounds VII, XII and XVI (100 µg/mL) showed an excellent activity against *S. aureus* with respect to standard drugs ampicillin and norfloxacin. Compounds VI, XII and XVI (100 µg/mL) showed more activity against *E. coli* with respect to the standard drugs ciprofloxacin,

TABLE-2
PHYSICAL CONSTANT OF SYNTHESIZED COMPOUNDS (V-XVI)

Comp. code	R	m.w. (g/mol)	m.p. (°C)	Yield ^a		Yield ^b	
				%	Time	%	Time
V	4-OCH ₃ phenyl	419	106-108	69	60	90	6
VI	4-CN phenyl	414	108-110	65	60	78	8
VII	Phenyl	389	154-156	70	60	82	6
VIII	4-Floro phenyl	407	111-113	72	60	84	10
IX	3-Thienyl	395	131-133	58	60	75	12
X	3,4,5-tri F phenyl	443	127-129	65	60	78	10
XI	3-NH ₂	404	129-131	62	60	76	10
XII	3-Bromo phenyl	468	108-110	72	60	84	8
XIII	3-Fluoro phenyl	407	110-112	69	60	80	8
XIV	4-Bromo phenyl	468	94-96	74	60	86	8
XV	2,4-di chloro phenyl	458	97-99	66	60	79	8
XVI	4-Ethyl phenyl	417	109-111	75	60	90	10

CH^a = Conventional heating method, MW^b = Microwave irradiation method.

*The m.p. of all synthesized compounds was measured by using open capillary apparatus.

TABLE-3
MIC VALUE OF 5-(4-(SUBSTITUTED-[1,1'-BIPHENYL]-4-YLMETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONES

Compd. No.	Minimum inhibitory concentration (µg/mL)					
	Antibacterial activity				Antifungal activity	
	Gram-positive bacteria		Gram-negative bacteria		<i>Aspergillus niger</i>	<i>Aspergillus clavatus</i>
	<i>Bacillus subtilis</i>	<i>Staphylococcus aureus</i>	<i>Escherichia coli</i>	<i>Salmonella typhi</i>		
V	500	500	250	250	1000	>1000
VI	100	200	100	100	100	500
VII	100	100	100	200	100	250
VIII	200	500	250	100	200	500
IX	500	250	200	500	500	500
X	500	250	200	500	500	500
XI	250	500	500	250	>1000	500
XII	100	100	200	125	500	500
XIII	500	200	250	250	500	>1000
XIV	250	250	500	500	>1000	500

chloramphenicol and ampicillin. Compounds VI and VIII showed activity against *S. typhi* with respect to standard drugs ciprofloxacin and chloramphenicol and comparative with respect to standard drug ampicillin.

Antifungal activity: Compounds VI, VII and XVI (100 µg/mL) showed more activity against *A. niger* with respect to standard drug griseofulvin and nystatin. From the obtained results, it can be interpreted that compounds with electron withdrawing group substitution showed more potent activity compared to those possessing electron donating group substitution.

Conclusion

In summary, a one-pot greener protocol is developed to provide a rapid and efficient synthesis of 5-(4-(substituted [1,1'-biphenyl]-4-yl-methoxy) benzyl)thiazolidine-2,4-diones from readily available starting materials like K₂CO₃ as catalyst and solvent mixture toluene:water:ethanol (5:0.5:0.5 mL) to minimize the impurity formation and also to improve the yield of final compounds. The advantages of microwave-assisted synthesis to minimize the reaction time and produced higher yields. The *in vitro* antimicrobial study of newly synthesized adducts indicates that compounds VI, VII, VIII, XII and XVI have shown moderate activity against different microbes.

ACKNOWLEDGEMENTS

The authors are thankful to the Department of Chemistry, Saurashtra University, Rajkot, India for providing the laboratory facilities and Centre of Excellence (CoE), NFDD Complex, Rajkot, India for providing the spectral data.

REFERENCES

1. D. Insuasty, J. Castillo, D. Becerra, H. Rojas and R. Abonia, Synthesis of Biologically Active Molecules through Multicomponent Reactions, *Molecules*, **25**, 505 (2020); <https://doi.org/10.3390/molecules25030505>
2. K. El-Adl, A.A. El-Helby, H. Sakr, R.R. Ayyad, H.A. Mahdy, M. Nasser, H.S. Abulhair and S.S.A. El-Hddad, Design, Synthesis, Molecular Docking, Anticancer Evaluations, and *in silico* Pharmacokinetic Studies of Novel 5-[(4-Chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione Derivatives as VEGFR-2 Inhibitors, *Arch. Pharm.*, **354**, e2000279 (2021); <https://doi.org/10.1002/ardp.202000279>
3. G. Bansal, P.V. Thanikachalam, R.K. Maurya, P. Chawla and S. Ramamurthy, An Overview on Medicinal Perspective of Thiazolidine-2,4-dione: A Remarkable Scaffold in the Treatment of Type 2 Diabetes, *J. Adv. Res.*, **23**, 163 (2020); <https://doi.org/10.1016/j.jare.2020.01.008>
4. V.S. Jain, D.K. Vora and C.S. Ramaa, Thiazolidine-2,4-diones: Progress Towards Multifarious Applications, *Bioorg. Med. Chem.*, **21**, 1599 (2013); <https://doi.org/10.1016/j.bmc.2013.01.029>
5. S. Mohanty, G.S. Reddy and A.C. Karmakar, Synthesis of New 5-Substituted-aminomethylene-thiazolidine-2,4-dione Derivatives as Potential Antibacterial Agents, *J. Applicable Chem.*, **3**, 82 (2014).
6. S.N. Nivtabishekam, M. Asad and V.S. Prasad, Pharmacodynamic Interaction of *Momordica charantia* with Rosiglitazone in Rats, *Chem. Biol. Interact.*, **177**, 247 (2009); <https://doi.org/10.1016/j.cbi.2008.09.034>
7. S. Shankar and S. Vuppu, *In vitro* Drug Metabolism and Pharmacokinetics of a Novel Thiazolidinedione Derivative, A Potential Anticancer Compound, *J. Pharm. Biomed. Anal.*, **179**, 113000 (2020); <https://doi.org/10.1016/j.jpba.2019.113000>
8. N. Trotsko, A. Przekora, J. Zalewska, G. Ginalska, A. Paneth and M. Wujec, Synthesis and *in vitro* Antiproliferative and Antibacterial Activity of New Thiazolidine-2,4-dione Derivatives, *J. Enzyme Inhib. Med. Chem.*, **33**, 17 (2018); <https://doi.org/10.1080/14756366.2017.1387543>
9. G. Bansal, S. Singh, V. Monga, P.V. Thanikachalam and P. Chawla, Synthesis and Biological Evaluation of Thiazolidine-2,4-dione-pyrazole Conjugates as Antidiabetic, Anti-inflammatory and Antioxidant Agents, *Bioorg. Chem.*, **92**, 103271 (2019); <https://doi.org/10.1016/j.bioorg.2019.103271>
10. S. Chandrappa, S.B. Benaka Prasad, K. Vinaya, C.S. Ananda Kumar, N.R. Thimmegowda and K.S. Rangappa, Synthesis and *in vitro* Antiproliferative Activity against Human Cancer Cell Lines of Novel 5-(4-methyl-benzylidene)thiazolidine-2,4-diones, *Invest. New Drugs*, **26**, 437 (2008); <https://doi.org/10.1007/s10637-008-9130-7>
11. V.S. Misra and N.S. Agarwal, Potential Anti-viral Compounds. II. Synthesis of Some Aromatic Aldehyde Thiosemicarbazones and Derivatives of 5-carboxymethyl Thiazolidine-2,4-dione, *J. Prakt. Chem.*, **37**, 150 (1968); <https://doi.org/10.1002/prac.19680370306>
12. M. Nomura, S. Kinoshita, H. Satoh, T. Maeda, K. Murakami, M. Tsunoda, H. Miyachi and K. Awano, (3-Substituted benzyl)thiazolidine-2,4-diones as Structurally New Antihyperglycemic Agents, *Bioorg. Med. Chem. Lett.*, **9**, 533 (1999); [https://doi.org/10.1016/S0960-894X\(99\)00039-6](https://doi.org/10.1016/S0960-894X(99)00039-6)
13. S.R. Atta-Allah, N.S. Ismail and I.F. Nassar, Synthesis, Design and Anti-inflammatory Activity of Novel 5-(Indol-3-yl)thiazolidinone Derivatives as COX-2 Inhibitors, *Lett. Drug Des. Discov.*, **18**, 525 (2021); <https://doi.org/10.2174/1570180817999201123164201>
14. D.G. Gojija, M.B. Vekariya, V.H. Kapupara, T.D. Bhatt, P.L. Kalavadiya and H.S. Joshi, Rapid, Simple and Efficient Microwave-Assisted Alkylation of 6-Acetyl-2H-Benzof[e][1,3]oxazine-2, 4(3H)-Dione, *ChemistrySelect*, **4**, 1738 (2019); <https://doi.org/10.1002/slct.201803607>
15. B.C. Ranu, A. Saha and R. Jana, Microwave-Assisted Simple and Efficient Ligand Free Copper Nanoparticle Catalyzed Aryl-Sulfur Bond Formation, *Adv. Synth. Catal.*, **349**, 2690 (2007); <https://doi.org/10.1002/adsc.200700289>
16. B.V. Varun, J. Dhineshkumar, K.R. Bettadapur, Y. Siddaraju, K. Alagiri and K.R. Prabhu, Recent Advancements in Dehydrogenative Cross Coupling Reactions for Csingle Bondc Bond Formation, *Tetrahedron Lett.*, **58**, 803 (2017); <https://doi.org/10.1016/j.tetlet.2017.01.035>
17. C.T. Yang, Z.Q. Zhang, Y.C. Liu and L. Liu, Copper-Catalyzed Cross-Coupling Reaction of Organoboron Compounds with Primary Alkyl Halides and Pseudohalides, *Angew. Chem.*, **123**, 3990 (2011); <https://doi.org/10.1002/ange.201008007>
18. J.-M. Oh, C.C. Venters, C. Di, A.M. Pinto, L. Wan, I. Younis, Z. Cai, C. Arai, B.R. So, J. Duan and G. Dreyfuss, U1 snRNP Regulates Cancer Cell Migration and Invasion *in vitro*, *Nat. Commun.*, **11**, 1 (2020); <https://doi.org/10.1038/s41467-019-13993-7>
19. G. Chatel and R.S. Varma, Ultrasound and Microwave Irradiation: Contributions of Alternative Physicochemical Activation Methods to Green Chemistry, *Green Chem.*, **21**, 6043 (2019); <https://doi.org/10.1039/C9GC02534K>